Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver ...
Researchers at The George Washington University, working with Weill Cornell Medicine, have identified specific gut bacteria ...
Immune checkpoint inhibitors have transformed the management of advanced malignancies by releasing the brakes on antitumour T-cell responses. Agents targeting programmed cell death protein 1 (PD-1), ...
GeoVax believes Gedeptin’s unique mechanism of localized tumor destruction combined with immune activation positions the program within a growing area of oncology focus: therapies designed to overcome ...
Annual Meeting featured a poster presentation by Dr. Akihiro Kumono and colleagues from Tokyo Women’s Medical University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results